BR0212620A - Métodos de tratamento de pacientes criticamente doentes sofrendo de angústia respiratória, e de pacientes criticamente doente possuindo uma condição que acarreta a angústia respiratória, e, uso de um composto de glp-1 - Google Patents

Métodos de tratamento de pacientes criticamente doentes sofrendo de angústia respiratória, e de pacientes criticamente doente possuindo uma condição que acarreta a angústia respiratória, e, uso de um composto de glp-1

Info

Publication number
BR0212620A
BR0212620A BR0212620-6A BR0212620A BR0212620A BR 0212620 A BR0212620 A BR 0212620A BR 0212620 A BR0212620 A BR 0212620A BR 0212620 A BR0212620 A BR 0212620A
Authority
BR
Brazil
Prior art keywords
respiratory distress
critically ill
ill patients
glp
compound
Prior art date
Application number
BR0212620-6A
Other languages
English (en)
Inventor
Suad Efendic
Joseph Anthony Jakubowski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0212620A publication Critical patent/BR0212620A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODOS DE TRATAMENTO DE PACIENTES CRITICAMENTE DOENTES SOFRENDO DE ANGúSTIA RESPIRATóRIA, E DE PACIENTES CRITICAMENTE DOENTES POSSUINDO UMA CONDIçãO QUE ACARRETA A ANGúSTIA RESPIRATóRIA, E, USO DE UM COMPOSTO DE GLP-1". Esta invenção refere-se ao uso de compostos de peptídeo semelhante a glucagon (GLP-1) para a redução da mortalidade e da morbidez associadas com doenças críticas no qual um paciente é predisposto à ou sofre de algum tipo de angústia respiratória.
BR0212620-6A 2001-10-01 2002-09-19 Métodos de tratamento de pacientes criticamente doentes sofrendo de angústia respiratória, e de pacientes criticamente doente possuindo uma condição que acarreta a angústia respiratória, e, uso de um composto de glp-1 BR0212620A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32633001P 2001-10-01 2001-10-01
PCT/US2002/028123 WO2003028626A2 (en) 2001-10-01 2002-09-19 Glucagon-like peptides (glp-1) and treatment of respiratory distress

Publications (1)

Publication Number Publication Date
BR0212620A true BR0212620A (pt) 2005-09-20

Family

ID=23271764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212620-6A BR0212620A (pt) 2001-10-01 2002-09-19 Métodos de tratamento de pacientes criticamente doentes sofrendo de angústia respiratória, e de pacientes criticamente doente possuindo uma condição que acarreta a angústia respiratória, e, uso de um composto de glp-1

Country Status (19)

Country Link
US (2) US20040235726A1 (pt)
EP (1) EP1443952A4 (pt)
JP (1) JP2005523877A (pt)
KR (1) KR20040040482A (pt)
CN (1) CN1561224A (pt)
BR (1) BR0212620A (pt)
CA (1) CA2462543A1 (pt)
CZ (1) CZ2004441A3 (pt)
EA (1) EA200400501A1 (pt)
EC (1) ECSP045044A (pt)
HR (1) HRP20040258A2 (pt)
HU (1) HUP0600437A2 (pt)
IL (1) IL160631A0 (pt)
MX (1) MXPA04002996A (pt)
NO (1) NO20041351L (pt)
PL (1) PL373846A1 (pt)
SK (1) SK1432004A3 (pt)
WO (1) WO2003028626A2 (pt)
ZA (1) ZA200402557B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
AU2003203146A1 (en) * 2002-02-07 2003-09-02 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
CA2551039C (en) 2003-12-16 2013-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogues of glp-1
TWI364292B (en) 2005-06-30 2012-05-21 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
JP2010043001A (ja) * 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Ｇｌｐ−１誘導体とその用途
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
EP2340049B1 (en) 2008-09-12 2015-11-11 Novo Nordisk A/S Method of acylating a peptide or protein
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
DE102009024229B3 (de) * 2009-06-08 2010-10-14 Salzsieder, Eckhard, Dipl.-Phys., Dr. rer.nat. Indikationseinrichtung zur automatisierten Bestimmung des individuellen Inkretin-Sensitivitäts-Indexes eines Probanden
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
ES2810153T3 (es) * 2012-03-01 2021-03-08 Novo Nordisk As Profármacos de GLP-1
US20230218556A1 (en) * 2020-05-01 2023-07-13 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
CN116847868A (zh) * 2021-01-29 2023-10-03 韩美药品株式会社 用于预防或治疗肺部疾病的包括gip衍生物或其长效共轭物的药学组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6271241B1 (en) * 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors

Also Published As

Publication number Publication date
WO2003028626A2 (en) 2003-04-10
CA2462543A1 (en) 2003-04-10
PL373846A1 (en) 2005-09-19
CN1561224A (zh) 2005-01-05
NO20041351D0 (no) 2004-03-31
EP1443952A4 (en) 2005-09-07
ECSP045044A (es) 2004-04-28
EA200400501A1 (ru) 2005-06-30
WO2003028626A3 (en) 2003-10-09
MXPA04002996A (es) 2004-07-15
US20080032932A1 (en) 2008-02-07
CZ2004441A3 (cs) 2004-11-10
KR20040040482A (ko) 2004-05-12
HUP0600437A2 (en) 2006-09-28
SK1432004A3 (sk) 2005-03-04
US20040235726A1 (en) 2004-11-25
EP1443952A2 (en) 2004-08-11
ZA200402557B (en) 2005-05-09
HRP20040258A2 (en) 2004-12-31
NO20041351L (no) 2004-06-30
IL160631A0 (en) 2004-07-25
JP2005523877A (ja) 2005-08-11

Similar Documents

Publication Publication Date Title
BR0212620A (pt) Métodos de tratamento de pacientes criticamente doentes sofrendo de angústia respiratória, e de pacientes criticamente doente possuindo uma condição que acarreta a angústia respiratória, e, uso de um composto de glp-1
PT1243263E (pt) Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
HUP0102879A2 (hu) Csontritkulás és klimaxos változások megelőzésére és/vagy kezelésére alkalmas készítmény
BR9808227A (pt) Preparação medicinal contendo gás inerte lipofìlico
BR9809968A (pt) Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
EP1421933A4 (en) USE OF STILBENE COMPOUNDS IN THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF DIABETES AND DISEASES ASSOCIATED WITH RETROVIRUS
BR0206847A (pt) Tratamento do diabete melito
BR0209992A (pt) Inibidor de pde4 e um agente anticolinérgico em combinação para o tratamento de doenças obstrutivas das vias respiratórias
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
BR9507656A (pt) Composto utilização de um composto composição farmacéutica e processos para o tratamento de um paciente que sofre de dor e para a preparação de um composto
BR0102116A (pt) Componentes para circuitos de respiração
DE50008336D1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
HUP0402328A2 (hu) Diabétesz mellitusz kezelésére szolgáló gyógyszerkészítmény
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
DE69412486D1 (de) Rekombinante viren und ihre verwendung bei der gentherapie
WO1992012715A3 (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
BRPI0410326A (pt) composição compreendendo um inibidor pde4 e inibidor pde5
ATE104855T1 (de) Verwendung von inositoltrisphosphat zur herstellung eines arzneimittels gegen knochenerkrakungen.
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
HUP0004813A2 (hu) Készítmények és eljárások légzési rendellenességek kezelésére
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
FI952094A0 (fi) Ihmisen serotoniinireseptoria (5-HT4B)koodaava DNA ja sen käyttö
BR0006269A (pt) Aplicação de dialquilpolissulfetos para o amassamento de borrachas naturais e de sìntese
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 DA RPI 2108 DE 31/05/2011.